The development of a financial toxicity patient‐reported outcome in cancer: The COST measure

@article{Souza2014TheDO,
  title={The development of a financial toxicity patient‐reported outcome in cancer: The COST measure},
  author={Jonas Ara{\'u}jo de Souza and Bonnie J. Yap and Fay J. Hlubocky and Kristen Wroblewski and Mark J. Ratain and David Cella and Christopher K. Daugherty},
  journal={Cancer},
  year={2014},
  volume={120}
}
Considering patients' experience is essential for optimal decision‐making. However, despite increasing recognition of the impact of costs on oncology care, there is no patient‐reported outcome measure (PROM) that specifically describes the financial distress experienced by patients. 
View on Wiley
accc-cancer.org
241 Citations
Highly Influential Citations
3
Background Citations
29
Methods Citations
18

241 Citations

Citation Type

Citation Type

Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)
TLDR
This data indicates that cancer and its treatment lead to increased financial distress for patients, and no standardized patient‐reported outcome measure has been validated to assess this distress.
Financial toxicity in patients with cancer attending a public Australian tertiary hospital: A pilot study
TLDR
The aim of this pilot study was to review the impact of financial toxicity in patients with cancer in an Australian public setting where there is a universal health care model.
Measuring financial toxicity in Australian cancer patients – Validation of the COmprehensive Score for financial Toxicity (FACT COST) measuring financial toxicity in Australian cancer patients
TLDR
This work aimed to confirm the validity and reliability of the FACT COST in Australian cancer patients, because the Australian healthcare funding structure is different to that in North America.
Advanced Cancer Patients' Medical Decision-Making While Experiencing Financial Toxicity
Advanced Cancer Patients’ Medical Decision-Making While Experiencing Financial Toxicity by Heather L. Morel MBA, Arizona State University West, 2000 BA, The Pennsylvania State University, 1990…
Overview: cost of cancer to the patient
TLDR
The articles in this Forum explore the many facets of financial costs in this context of cancer and how Australia is no exception.
Recognizing the Financial Burden of Cancer Patients in Clinical Trials.
TLDR
Future research efforts should focus on developing formal screening tools to identify and monitor for financial burden among clinical trial participants.
The cost of cure: Examining objective and subjective financial toxicity in head and neck cancer survivors
TLDR
Financial toxicity is associated with particular socioeconomic characteristics which, if understood, would assist the development of pre-treatment screening tools to detect at-risk individuals and intervene early in the HNC cancer survivorship trajectory.
Cost-related health literacy: a key component of high-quality cancer care.
Because cancer treatment can result in both short- and long-term financial harm known as financial toxicity; the Institute of Medicine has issued a challenge to improve patients' understanding of…
Financial toxicity in cancer care.
TLDR
The most relevant literature on financial toxicity in cancer care is reviewed, and potential predictors of financial toxicity, and the recent development of instruments to help clinicians and researchers quantify financial burden are discussed.
Quantifying treatment preferences and their association with financial toxicity in women with breast cancer
The objective of the current study was to understand treatment preferences and their association with financial toxicity in Patient Advocate Foundation clients with breast cancer.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 68 REFERENCES
Toward patient-centered drug development in oncology.
  • E. Basch
  • Medicine, Biology
    The New England journal of medicine
  • 2013
TLDR
As patients live longer with cancer, they must increasingly choose among agents with varying efficacy–toxicity balances, and regulators and industry continue to prioritize survival-based end points rather than patient-experience end points in cancer-drug development.
The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience.
TLDR
Insured patients undergoing cancer treatment and seeking copayment assistance experience considerable subjective financial burden, and they may alter their care to defray out-of-pocket expenses.
The cost of cancer care: there is more than one elephant in the room.
TLDR
The current system rations care in an irrational way, and this irrational rationing is going to worsen, for the costs are simply not sustainable nor are they justifiable by almost any metric used.
Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA
  • W. B. Hout
  • Medicine
    Nature Clinical Practice Rheumatology
  • 2009
TLDR
The impact of biologic therapy for rheumatoid arthritis on quality of life has clear relevance to studies of the cost-effectiveness of these agents, however, several deficiencies in current economic evaluations need to be overcome to enhance the utility of such research.
Cancer Patients’ Trade-offs Among Efficacy, Toxicity, and Out-of-Pocket Cost in the Curative and Noncurative Setting
TLDR
Higher income patients may be more likely to focus on survival, whereas those of lower socioeconomic status may beMore likely to avoid expensive treatment, regardless of survival or toxicity, which raises the possibility that insurance plans with greater cost-sharing may have the unintended consequence of increasing disparities in cancer care.
Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards.
Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology.
  • E. Basch, A. Abernethy, +12 authors S. Tunis
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
Adherence to methodologic standards for the selection, implementation, and analysis/reporting of PRO measures will lead to an understanding of the patient experience that informs better decisions by patients, providers, regulators, and payers.
Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis.
TLDR
A significant proportion of patients undergoing adjuvant chemotherapy for stage III colon cancer may experience financial hardship, despite having health insurance coverage, and younger age, lower income, and unemployment or disability were most closely associated with treatment nonadherence.
Functional Assessment of Cancer Therapy (FACT-G): Non-response to individual questions
TLDR
Seven methods of scoring the FACT-G are compared and case deletion is the worst approach and results in clinically significant bias when the missing responses were non-random and a lack of precision when the rate of non-response was high.
Full disclosure--out-of-pocket costs as side effects.
Because treatments can impose out-of-pocket costs that may impair patients' well-being, physicians should disclose the financial consequences of treatment alternatives just as they inform patients…
...
1
2
3
4
5
...